Pre-filled Syringes San Francisco Conference 2020

SMi Group 14 - 15 September 2020, San Francisco, USA.
The global pre-filled syringes market was valued at $4.9 billion in 2018 and with the rapid growth of the industry, is expected to exceed $9.7 billion by 2025. With that in mind, this event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation, new digital technology trends, human studies and innovative design and delivery systems within the prefilled syringe industry.

As part of SMi's leading Injectable conference series, we will assess digital health and connected devices, biologics, biosimilars and biocompatibility for drug device combination products, platform and device selection, regulatory insights and explore the West Coast's biotech innovators. This two-day agenda offers you peer-to-peer networking with Global Product Managers, Device Testing Managers, Senior Device Engineers, Heads of Device Development, Heads of Formulation and Drug Process Development, and many more.

Plus, a workshop on human factors and risk management:

  • Integration of Human Factors Engineering processes in risk management saves time and money in product development
  • Effective identification of use-related risk helps inform constructive design decisions
  • Mitigation of use-related risk improves treatment outcomes for end users
  • Understanding the methods used to assess use-related risk will improve the efficiency and acumen of your organization

Benefits of attending

  • EXPLORE the latest industry case studies in platform approaches and connected devices
  • GAIN insights from leading industry and regulatory experts on the pre-filled syringes environment
  • HEAR from local biotechs of San Francisco and the West Coast to learn about new innovations in the pre-filled syringes space
  • ENGAGE in the key challenges and topics of the field in two interactive half-day workshops

Chairs for 2020

  • Shannon Clark, Principal, UserWise
  • Steven Badelt, Founder and Managing Partner, Suttons Creek, Inc.

Featured 2020 speakers include

  • Kristina Lauritsen, Combination Products Regulatory Advisor, FDA/CDER
  • Manuela Gazzard, Group Executive Director Regulatory Services Healthcare, BSI
  • Christine Lynn Lanning, Distinguished Scientist, Device Area Leader, Safety Assessment/Merck & Co., Inc
  • Khaudeja Bano, Senior Medical Director, Abbott Laboratories
  • Jace Blackburn, Smart Device Engineer, Genentech
  • Michael Koby, Senior Principle Scientist, Pfi zer
  • James Leamon, Director of Biologics Device Development, Jazz Pharmaceuticals
  • Walter Goodwin, Device Engineer, Device Development & Clinical Packaging Engineering, Gilead Sciences
  • Katie Atkinson, Manager Human Factors Engineering, Bigfoot Biomedical

Early-bird rates

  • Book by 29th May and save £300
  • Book by 30th June and save £200

For further information and to register, please visit:
http://www.prefilled-sanfrancisco.com/wpnwl

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

COVID-19 containment shaped by strength, duration …

"Much of the discussion so far related to the future trajectory of COVID-19 has rightly been focused on the effects of seasonality and non-pharmaceutical interventions [N...

Scientists identify synthetic mini-antibody to com…

The ability of SARS-CoV-2 to infect cells depends on interactions between the viral spike protein and the human cell surface protein ACE2. To enable the virus to hook ont...

New drug candidate for the treatment of COVID-19

Researchers from the University of Kent, the Goethe-University in Frankfurt am Main (Germany), and the Hannover Medical School (Germany) have identified a drug with the p...

Cancer treatment could be replicated for COVID-19

Beta-blockers could potentially be used to treat COVID-19, according to a new international study by Italian and Australian scientists. University of South Australia c...

European Commission approves contract with BioNTec…

Today, the European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses ...

Pre-existing coronavirus antibodies could help pro…

Researchers at the Francis Crick Institute and University College London have found that some antibodies, created by the immune system during infection with common cold c...

Remdesivir for COVID-19: FDA approved but still un…

The United States has become the epicenter of the world in the ever increasing pandemic of COVID-19. While public health prevention strategies of social distancing, crowd...

Fluvoxamine may prevent serious illness in COVID-1…

In a preliminary study of COVID-19 patients with mild-to-moderate disease who were attempting to recover in their homes, researchers at Washington University School of Me...

The Sputnik V COVID-19 vaccine efficacy amounted t…

The National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Rus...

Medicago and GSK announce start of Phase 2/3 clini…

Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK have announced the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate f...

Lilly's neutralizing antibody bamlanivimab (LY-CoV…

The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for Eli Lilly and Company's (NYSE: LLY) investigational neutralizing antibody bamlan...

Swissmedic begins rolling review of Moderna's mRNA…

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for...